



SERES
THERAPEUTICS™

Seres Therapeutics Announces Participation at Two Upcoming Investor Conferences

February 3, 2017

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 3, 2017-- Seres Therapeutics Inc., (NASDAQ:MCRB), a leading microbiome therapeutics platform company, today announced that management will participate in two upcoming investor conferences:

- Canaccord Genuity Rare Disease and BioPharma 1x1 Day on Tuesday, February 7, 2017 in New York, NY
- 6th Annual Leerink Partners Global Healthcare Conference on Wednesday, February 15, 2017 in New York, NY; presentation at 11:00 a.m. ET

Live audio webcast of the Leerink presentation be available under the "Investors and Media" section of Seres' website. A replay of the presentation will become available approximately one hour after the event and will be archived for 21 days.

About Seres Therapeutics

Seres Therapeutics, Inc. is a leading microbiome therapeutics platform company developing a novel class of biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome, where the natural state of bacterial diversity and function is imbalanced. The Phase 2 study of Seres' program SER-109 has been completed in multiply recurrent *C. difficile* infection. Seres' second clinical candidate, SER-287, is being evaluated in a Phase 1b study in patients with mild-to-moderate ulcerative colitis (UC). Seres is also developing SER-262, the first ever synthetic microbiome therapeutic candidate, in a Phase 1b study in patients with primary *C. difficile* infection. For more information, please visit www.serestherapeutics.com. Follow us on Twitter @SeresTx.



View source version on businesswire.com: <http://www.businesswire.com/news/home/20170203005081/en/>

Source: Seres Therapeutics Inc.

Seres Therapeutics
Carlo Tanzi, Ph.D., 617-203-3467
Head of Investor Relations and Corporate Communications
Ctanzi@serestherapeutics.com